Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperbaric oxygen for acute idiopathic sudden sensorineural hearing loss
2024-510798-84-00Phase 3Authorised
- Sponsor
- Helse Bergen
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in idiopathic sudden sensorineural hearing loss (ISSNHL) comparing Standard of care + hyperbaric oxygen therapy with Standard of care alone (2 arms). Primary endpoint: Mean absolute pure tone average at week 14. Planned start Oct 2024; status: authorised.
02
Drugs
oxygen
03
Conditions
idiopathic sudden sensorineural hearing loss (ISSNHL)
Beyond the preview
Go deeper on 2024-510798-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510798-84-00.